Famciclovir
| Evidence Level: L4 | Predicted Indications: 9 |
Table of Contents
Famciclovir: From Herpesvirus Infections to Post-Infectious Neuralgia
One-Sentence Summary
Famciclovir is an oral antiviral prodrug of penciclovir, used against herpesvirus infections such as herpes zoster. The TxGNN model predicts it may be effective for post-infectious neuralgia (most plausibly postherpetic neuralgia, PHN), but the evidence is thin: 2 clinical trials were retrieved, neither testing famciclovir, and no publications were found.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Herpesvirus infections such as herpes zoster (the license records contain no indication text; this reflects the drug’s known use) |
| Predicted New Indication | Post-infectious neuralgia |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| US Market Status | Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Famciclovir is a prodrug of penciclovir. Penciclovir inhibits the DNA polymerase of varicella-zoster virus (VZV) and shortens active viral replication during acute herpes zoster.
PHN is the most common complication of herpes zoster, and here “post-infectious neuralgia” most plausibly refers to it. If early antiviral therapy limits nerve damage during the acute phase, the risk of later chronic neuralgia could fall. This link is plausible but indirect.
Neither retrieved trial tests famciclovir for preventing or treating PHN. The prediction therefore rests mainly on the model score and mechanistic reasoning.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03120962 | Not applicable | Unknown | 140 | Early oxycodone during acute herpes zoster to prevent PHN. Famciclovir is not the studied drug (at most background antiviral therapy). |
| NCT06798662 | Not applicable | Not yet recruiting | 120 | Nerve block plus pulse radiofrequency for acute zoster pain. Not a famciclovir study, and there are no results yet. |
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA202438 | Famciclovir (Proficient Rx LP; also Camber Pharmaceuticals) | Film-coated tablet | Not provided in the record |
| ANDA201022 | Famciclovir (Macleods Pharmaceuticals) | Film-coated tablet | Not provided in the record |
| ANDA091114 | Famciclovir (Rising Pharma Holdings) | Film-coated tablet | Not provided in the record |
All listed products are generic (ANDA) oral tablets.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The link between famciclovir and PHN is biologically plausible, but no retrieved study tests famciclovir for this use. The evidence is limited to model prediction and mechanistic reasoning, so this stays a research question.
To proceed, the following is needed:
- Trials or observational studies testing famciclovir for PHN prevention or treatment
- Package insert warnings and contraindications, which are currently missing
- Detailed mechanism of action data from DrugBank
- A decision on whether to prioritize the same pack’s chickenpox prediction, which has completed Phase 3 famciclovir studies in VZV disease (NCT01327144, NCT00098046). Its primary varicella efficacy is less direct, and pediatric dosing and safety need confirmation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.